Clinical trials: Schizophrenia and Disorders With Psychotic Features
Mood Disorders, Anxiety Disorders
Clinical Study Evaluating Pharmacogenomics-informed Pharmacotherapy Versus Dosing as Usual in Psychiatric Disorders
A 24-week, patient- and rater-blinded, two-arm, parallel-group controlled, and multi-centre randomized clinical trial (RCT) to establish the benefits of pharmacogenetics-informed pharmacotherapy versus dosing as usual (DAU) in…
- Conditions
- Mood Disorders, Anxiety Disorders, Psychotic Disorders
- Trial name
- PSY-PGx (NCT05656469)
- Testing
- Personalised medication advice based on pharmacogenetic testing
- Where
- 9 sites in United States, Germany and 5 more
- Volunteers
- 2,500 people
- Sponsor
- Parnassia Groep
Schizophrenia
A Phase I Clinical Trial to Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of KR23248 Capsules in Healthy Adult Subjects
This study aims to investigate the safety, tolerability and pharmacokinetic characteristics of KR23248 capsules in healthy subjects. This study will be conducted in China.
- Trial name
- NCT07585383
- Testing
- KR23248
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- Jiangxi Kvvit Pharmaceutical Co., Ltd.
Obsessive-Compulsive Disorder, Obsessive-Compulsive Behavior
Rituximab Treatment for Psychosis And/or Obsessive Compulsive Disorder with Probable Immune System Involvement
The primary objective for this study is to evaluate whether Rituximab as compared to placebo is a clinically effective treatment for a subgroup of patients suffering from psychosis and/or obsessive-compulsive disorder (OCD) or…
- Conditions
- Obsessive-Compulsive Disorder, Obsessive-Compulsive Behavior, Schizophrenia, Delusional Disorder
- Trial name
- Ra-P-OCD (NCT04323566)
- Testing
- Rituximab
- Where
- Sweden
- Volunteers
- 40 people
- Sponsor
- Uppsala University Hospital
Mood Disorders, Anxiety Disorders
Reconnecting to Ourselves and Others in Virtual Meetings (ROOM)
This study aimed to determine the feasibility and acceptability of delivering Resilience Training in multi-user virtual reality.
- Conditions
- Mood Disorders, Anxiety Disorders, Psychotic Disorders
- Trial name
- NCT06360562
- Testing
- Resilience Training
- Where
- United States
- Volunteers
- 174 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
Schizophrenia Sib-Pairs
A Genetic Linkage Study of Schizophrenia
We propose to study 900 sib-pairs with the disorder. Our Specific Aims are: 1) To clinical assess a pedigree sample having adequate power to detect genes for schizophrenia. 2) To conduct a genome scan to find such loci.
- Trial name
- NCT00155688
- Volunteers
- 2,400 people, healthy volunteers welcome
- Sponsor
- National Taiwan University Hospital
Schizophrenia
A Pharmacokinetics Study to Evaluate Safety and Tolerability of JNJ-37822681 in Participants With Stable Schizophrenia
The purpose of this study is to evaluate safety, tolerability and pharmacokinetics (explores what the body does to the drug) of JNJ-37822681 in participants with stable schizophrenia (psychiatric disorder with symptoms of…
- Trial name
- NCT01812642
- Testing
- JNJ-37822681
- Where
- 6 sites in Belgium, Germany and 3 more
- Volunteers
- 33 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Schizophrenia, Psychosis
Prefrontal Cortical Engagement Through Non-Invasive Brain Stimulation in Schizophrenia
Cognitive impairments in schizophrenia are the most debilitating aspect of the illness and poorly treated by current medications.
- Trial name
- NCT02975973
- Testing
- transcranial direct current stimulation
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Baylor College of Medicine
Cannabis, Psychotic Disorders
Cannabinoids and Cerebellar-Motor Functioning
The purpose of this study is to characterize the dose-related effects of delta-9-tetrahydrocannabinol (∆9-THC) in healthy individuals on cerebellum-dependent motor functions.
- Trial name
- NCT01853020
- Testing
- THC
- Where
- United States
- Volunteers
- 57 people, healthy volunteers welcome
- Sponsor
- Yale University
Severe Mental Disorder, Smoking Cessation
Tobacco Intensive Motivational and Estimate Risk
Randomized, open label, prospective study with a 12-month follow-up period. The primary objective evaluates the effectiveness of an intensive anti-smoking programme that informs patients of their individual risk of lung damages…
- Conditions
- Severe Mental Disorder, Smoking Cessation, COPD
- Trial name
- NCT03583203
- Testing
- personalized information about lung damage
- Where
- Spain
- Volunteers
- 230 people
- Sponsor
- Hospital Universitario Reina Sofia de Cordoba
Schizophrenia
Risperidone Augmentation in Patients With Schizophrenia
We propose a double-blind, placebo-controlled trial to study the effectiveness and tolerability of adding risperidone to stable yet only partially remitted patients with schizophrenia maintained on clozapine.
- Trial name
- NCT00289861
- Testing
- Risperidone
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Massachusetts General Hospital
Schizophrenia
Autobiographical Memory Organization in Schizophrenia
The aim of the study is to investigate the temporal organization of autobiographical memory in patients with schizophrenia. Patients and control participants will be invited separately to participate in a 1hour walk in the city…
- Trial name
- AMOrSchiz (NCT02570594)
- Testing
- questionary
- Where
- France
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- University Hospital, Strasbourg, France
Childhood Schizophrenia, Psychotic Disorder
Comparison of Clozapine vs Olanzapine in Childhood-Onset Psychotic Disorders
The purpose of this study is to compare the effectiveness and side effects of the drugs clozapine and olanzapine in children and adolescents with schizophrenia and psychoses.
- Conditions
- Childhood Schizophrenia, Psychotic Disorder, Schizophrenia
- Trial name
- NCT00001656
- Testing
- Olanzapine, Clozapine
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- National Institute of Mental Health (NIMH)
Depressive Disorders, Psychotic Disorders
Safety of Org 34517 900 mg in Patients Who Received Org 34517 in a Previous Trial (Study 28133/P05842)
Patients who participated in the previous trial 28130, who were eligible, were entered into this trial. Patients who were randomized to placebo in the previous trial 28130 continued on placebo while patients who were randomized…
- Conditions
- Depressive Disorders, Psychotic Disorders, Depression
- Trial name
- NCT00844922
- Testing
- SCH 900636
- Volunteers
- 16 people
- Sponsor
- Merck Sharp & Dohme LLC
Cognitive Impairment Associated With Schizophrenia (CIAS)
A Study to Evaluate KYN-5356 in Adults With Cognitive Impairment Associated With Schizophrenia
This is a Phase 2, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety, Pharmacokinetic (PK) and Pharmacodynamic (PD) effects of 3 different dose regiments of KYN-5356 and placebo for 28 days.
- Trial name
- NCT07191483
- Testing
- KYN-5356 low dose, KYN-5356 Medium Dose, KYN-5356 High Dose
- Where
- 15 sites in United States
- Volunteers
- 149 people
- Sponsor
- Kynexis B.V.
Schizophrenia
Long-term Study of Asenapine in Participants With Residual Subtype, Receiving Multiple or/and High Dose Drugs, or Treatment Refractory Schizophrenia (P06238)
This is a multi-site, open-label fixed-flexible dose long-term study of asenapine in participants with schizophrenia. Participants in this study consist of schizophrenia with residual subtype or receiving high dose/multiple…
- Trial name
- NCT01244828
- Testing
- Asenapine
- Volunteers
- 157 people
- Sponsor
- Organon and Co
Psychiatric Disorders, Depression - Major Depressive Disorder
Implementing Action-Based Cognitive Remediation for Transdiagnostic Cognitive Difficulties in a Tertiary Mental Health Hospital
Psychiatric conditions are each defined by different set of symptoms, however, they often share common characteristics such as impairments in cognitive and social functioning.
- Conditions
- Psychiatric Disorders, Depression - Major Depressive Disorder, Schizophrenia and Other Psychotic Disorders, Anxiety and Mood Disorders
- Trial name
- NCT07506070
- Testing
- Action-Based Cognitive Remediation
- Volunteers
- 160 people
- Sponsor
- The Royal Ottawa Mental Health Centre
Schizophrenia, Cognitive Impairment
From Brain Currents to Interpersonal Flow: Investigating the Social Processing Stream of Schizophrenia
The overall objective of this project is to identify the neural signature of the impaired ability to relate socially seen in individuals with schizophrenia.
- Conditions
- Schizophrenia, Cognitive Impairment, Social Competence
- Trial name
- ecoval (NCT03543553)
- Testing
- This is not an intervention study
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Oslo University Hospital
Schizophrenia
Efficacy of Bifeprunox in Patients With Schizophrenia
The primary purpose of the study is to evaluate the efficacy of bifeprunox in the maintenance phase of schizophrenia compared to placebo.
- Trial name
- NCT00658645
- Testing
- Bifeprunox, Quetiapine
- Where
- 38 sites in Bulgaria, China and 6 more
- Volunteers
- 227 people
- Sponsor
- H. Lundbeck A/S
Psychoses, Metabolic Syndrome
Targeted Health Dialogues for Individuals With Psychosis Spectrum Disorders
People with psychotic disorders are at a higher risk of premature death than the general population. Adverse lifestyle factors contribute to this reduced life expectancy; such factors may include high consumption of tobacco and…
- Trial name
- NCT07888894
- Testing
- Targeted Health Dialogues
- Volunteers
- 60 people
- Sponsor
- Uppsala University
Schizophrenia
Ashwagandha Added to Risperidone for Quality of Life and Inflammation in Schizophrenia
Schizophrenia is a chronic mental health disorder that affects thinking, emotions, behavior, and quality of life. Although antipsychotic medications such as risperidone are commonly used to manage schizophrenia, some patients…
- Trial name
- NCT07917637
- Testing
- Withania somnifera (Ashwagandha) Extract, Risperidone 4mg/day
- Where
- Indonesia
- Volunteers
- 60 people
- Sponsor
- Athitah Pratiwi
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.